健择联合顺铂治疗晚期非小细胞肺癌临床观察.docVIP

健择联合顺铂治疗晚期非小细胞肺癌临床观察 　 ; 作者：顾爱琴，韩宝惠，沈洁，戚大江，熊丽纹 毕业论文 【关键词】; 非小细胞肺癌；健择；顺铂；化疗 毕业论文 　　［摘要］; 目的; 观察健择与顺铂联合化疗方案(GP方案)治疗晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。方法; 对82例Ⅲ期及Ⅳ期非小细胞肺癌患者给以GP方案治疗。健择1250mg/m2静滴第1、8天，DDP 70～80mg/m2静滴第1天,21天为1个周期，每例患者至少治疗2周期。结果; 全组部分缓解30例，稳定44例、进展8例；总有效率为36.6%。初治病人有效率为43.2%，复治病人有效率为28.9%。全组中位生存期9.2个月，1年生存率为37.8%。最常见的毒副反应为骨髓抑制，Ⅲ～Ⅳ度白细胞及血小板降低发生率分别为28.0%和24.4%，其余毒副反应较轻微，可以耐受。结论; 健择联合顺铂化疗方案一线治疗或二线治疗晚期非小细胞肺癌均有较好疗效,毒性反应轻，患者的耐受性较好。 毕业论文 　　［关键词］; 非小细胞肺癌；健择；顺铂；化疗 ; 　　Clinical observation of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer 毕业论文 　　［Abstract］; Objective; To evaluate the therapeutic effects and toxicity reaction of gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).Methods; 82 patients with NSCLC in stage Ⅲ and Ⅳ were treated with gemcitabine 1250mg/m2 by intravenous infusion on 1st and 8th days,and cisplatin 70～80mg/m2; by intravenous infusion on 1st in a 21-day cycle.Each patient was treated at least for 2 cycles.Results; Of the 82 patients,30 cases got partial response,44 cases had stable disease,and 8 cases had progressive disease,with an overall response rate of 36.6%(30/82).The response rate was 43.2%(19/44) in the initial patients and 28.9%(11/38) in the retreated patients(P＞0.05).The medium survivals were 9.2 months.The 1-year survival rates were 37.8%.The main toxicities were leukopenia (incidence of 28.0% for grade Ⅲ and Ⅳ) and thrombocytopenia (incidence of 24.4% for grade Ⅲ and Ⅳ).Conclusion; The combination of gemcitabine and cisplatin is feasible, well-tolerated and effective scheme in either first-line or second-line treatment of advanced NSCLC. 毕业论文 　　［Key words］; non-small cell lung cancer;gemcitabine;cisplatin;chemotherapy 毕业论文 　　肺癌是严重威胁人类健康及生命的最常见的恶性肿瘤之一，肺癌发病率及死亡率逐年提高，而非小细胞肺癌(NSCLC)的发病率占肺癌的70%～80%，其中约2/3的患者确诊时已失去手术机会，对这些患者主要采取以化疗为主的综合治疗。健择为阿糖胞苷的类似物，属于细胞周期特异性抗代谢类药物，而铂类药物是NSCLC联合化疗的重要基础药物，研究已表明两者间有协同作用［1］。目前健择联合顺铂化疗方案是标准的一线方案之一，已广泛应用于临床。我们自2002年3月～2